Sarepta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
All right. Let's go ahead and get started. Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by [Malcolm Cuneo] and Priyanka Grover from the team. Our next presenting company is Sarepta. And presenting on behalf of the company, we have CEO, Doug Ingram. Doug?
Thank you, Anupam. Thanks, everyone, for joining us today, and thanks for those joining us online as well. We'll go 2 slides forward. I'll try my best to -- for those online, to remember try to reference slide numbers as I know that the slides don't automatically go forward. So for the last many years, we've been building, and we've been building frenetically.
We gathered together the pipeline and the people. We built a balance sheet. We gained multiple approvals. We've served the Duchenne community. We've been advancing our pipeline. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |